Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Notification of managers' transactions
ANNOUNCEMENT NO. 274 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of CFO Kim Nicolajsen in the attached PDF document.For further information, please contact:Kim Nicolajsen, CFO...
Nasdaq GlobeNewswire
13/09/2024
Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients…
KINE-101 is a novel nanopeptide and a disease modifier that controls both humoral immunity and cell-mediated immune responses by activating Treg cells. KINE-101 received FDA clearance for the Phase I study on September, 2021. The study was conducted in 40 healthy individuals in five cohorts assessed over 42 days. The design included four cohorts receiving intravenously administered ascending doses of KINE-101 (10, 30, 100, and 300 mg), and a cohort that received 96.8 mg of KINE-101…
PR Newswire
13/09/2024
Valneva Announces the Success of its Private Placement Raising approximately €60…
Saint-Herblain (France), September 13, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a final amount of €61,180,000. Peter Bühler, Valneva's Chief Financial Officer, commented, “We would like to thank our existing shareholders for their continued support, as well as the new healthcare specialist investors joining us through this...
Nasdaq GlobeNewswire
13/09/2024
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous…
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous(IV) Tecentriq 1,2 New subcutaneous (SC) option reduces treatment time to approximately seven minutes, compared with 30-60 minutes for IV infusion 2 Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq Hybreza TM...
Nasdaq GlobeNewswire
13/09/2024
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering.Registration statements relating to the shares being sold in the offering have been filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on September 12, 2024. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus...
Nasdaq GlobeNewswire
13/09/2024
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public…
BOSTON and LONDON, Sept.12, 2024(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering...
Nasdaq GlobeNewswire
13/09/2024
Valneva Announces the Launch of a Private Placement of Ordinary Shares for…
Saint-Herblain (France), September 12, 2024–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6 million new ordinary shares (the “ Offer Shares ”) at a price of €2.66 per Offer Share to certain categories of investors via a private placement through an accelerated bookbuilding process starting immediately. Context of the Offering The...
Nasdaq GlobeNewswire
12/09/2024
Stapokibart Was Granted Marketing Approval From National Medical Products…
The study showed that at week 52, the rates of achieving EASI-75 for the Stapokibart group and the placebo-to-Stapokibart group were 92.5% and 88.7%, respectively. The EASI-90 response rates were 77.1% and 65.6%, respectively. The rates of achieving an IGA score of 0 or 1 point with a reduction of ≥ 2 points from baseline were 67.3% and 64.2%, respectively. Long-term treatment with Stapokibart can consistently improve dermatitis symptoms and quality of life in subjects with moderate-to-severe…
PR Newswire
12/09/2024
SPINEWAY : Great success at the 24th AMCICO Congress in Mexico
Press release Ecully, September 12, 2024 – 6 p.m.SPINEWAYGreat success at the 24th AMCICO Congress in Mexico Spineway, a specialist in innovative implants for the treatment of severe spine disorders, took part in the24thAMCICO (Asociación Mexicana de Cirujanos de Columna)congress inCancúnfrom September 4 to 8, 2024.This annual congress of spine surgeons is a flagship event for the spine surgery sector in Mexico, the largest market in Central and...
Nasdaq GlobeNewswire
12/09/2024
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…
Disclosure of Share Capital and Voting Rights Outstandingas of August 31, 2024(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Charenton-le-Pont, France (September 12, 2024 - 6:00 pm)– As of August 31, 2024, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses,...
Nasdaq GlobeNewswire
12/09/2024
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…
Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1...
Nasdaq GlobeNewswire
12/09/2024
Vascular Stents Market to Grow from USD 11.4B in 2024 to USD 15.6B by 2029 |…
Browse in-depth TOC on "Vascular Stents Market" Browse in-depth TOC on "Vascular Stents Market" 620 - Tables 53 - Figures 426 - Pages Technological Advancements The vascular stent market is segmented by technology into covered stents, drug-eluting stents, bare metal stents, and bioabsorbable stents. As of 2023, drug-eluting stents hold the largest market share due to their clinical benefits, including a lower incidence of restenosis. These stents are coated with...
PR Newswire
12/09/2024
HeyGears to Launch New UltraCraft Reflex Series 3D Printer: Designed for…
HeyGears is inviting industry professionals and the 3D printing community to join the product launch event, which will be streamed on YouTube and Facebook on September 19, 2024, at 6:00 PM PDT. The event will offer a first look at the latest UltraCraft Reflex Series 3D printer, software updates, as well as newly developed resins, and provide insights into HeyGears' next steps in 3D printing. HeyGears is inviting industry professionals and the 3D printing community to join the product launch...
PR Newswire
12/09/2024
Surgical Microscopes Market Size to Grow USD 1,399.09 Million by 2030 at a CAGR…
Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-0N72/Surgical_Microscopes_Market Get Free Sample: https://reports.valuates.com/request/sample/ALLI-Auto-0N72/Surgical_Microscopes_Market Major Factors Driving Surgical Microscopes Market The global market for surgical microscopes is witnessing significant growth, driven by increasing demand across various medical fields such as neurosurgery, ophthalmology, ENT, and orthopedics. These microscopes enhance...
PR Newswire
12/09/2024
Landscaping Services Market to Reach $401.4 Billion, Globally, by 2034 at 3.8%…
Request The Sample PDF Of This Report: https://www.alliedmarketresearch.com/request-sample/A06341 Request The Sample PDF Of This Report:https://www.alliedmarketresearch.com/request-sample/A06341 Prime determinants of growth The rise in trend of sustainable and eco-friendly practices, such as xeriscaping and the use of native plants, has driven demand for landscaping services as clients seek environmentally responsible options in recent times. Technological innovations,...
PR Newswire
12/09/2024
B.More Collaborator, Dr. Michael Bogenschutz, Awarded NIAAA Grant for Psilocybin…
According to Carey Turnbull, Co-founder, and CEO of B.More Inc., "The awarding of this NIAAA grant is a significant recognition of Dr. Bogenschutz's pioneering work in developing new treatment modalities for alcohol use disorder. Building on the groundbreaking results of his well-publicized Phase 2a study on psilocybin for AUD, this trial has the potential to pave the way for more effective treatments for AUD and other substance use disorders, providing new hope for millions struggling with…
PR Newswire
12/09/2024
A Pioneering Achievement Strengthening the Kingdom's Leadership in Medicine
KFSHRC Performs the World's First Fully Robotic Heart Transplant RIYADH, Saudi Arabia, Sept.12, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) successfully performed the world's first fully robotic heart transplant on a 16-year-old patient suffering from end-stage heart failure. This pioneering achievement, overcoming the significant medical challenges associated with such procedures, reinforces KFSHRC's ability to innovate medical...
Nasdaq GlobeNewswire
12/09/2024
Sobi® and Enable Injections announce agreement to develop and distribute…
"We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment," said "We are dedicated to advancing innovative solutions for the treatment of rare diseases, and this agreement with Enable Injections marks an important step in fulfilling that commitment," said Lydia Abad-Franch, MD, Head of R&D, Medical Affairs, and Chief Medical Officer at Sobi…
PR Newswire
12/09/2024
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
Jane, was awarded an Order of the British Empire (OBE) and Scrip's Lifetime Achievement Award in 2019 for services to drug discovery, development and biotechnology. She is a Venture Partner at SV Health Investors, has served as a Director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, and was Chair of the Board of Directors of the UK BioIndustry Association. Jane, was awarded an Order of the British Empire (OBE) and Scrip's Lifetime...
PR Newswire
12/09/2024
CIZZLE BIOTECHNOLOGY ANNOUNCES GROUNDBREAKING COLLABORATION WITH MOFFITT CANCER…
A Pioneering Study: A Pioneering Study: This collaboration is part of Moffitt's Phase 2 program, "Using Biomarkers for Diagnosis, Risk Stratification of Post-treatment Recurrence and Long-Term Survival of Lung Cancer." Led by Dr. Lary Robinson, Director of Moffitt's Lung Cancer Early Detection Center, the study will evaluate Cizzle's CIZ1B biomarker's ability to detect lung cancer early, aiming to reduce false positives and unnecessary interventions caused by CT scans. Strategic US...
PR Newswire
12/09/2024
Biogen Board Appoints Two New Independent Directors
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development BiogenInc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for...
Nasdaq GlobeNewswire
12/09/2024
Natural Dyes Market worth $6.4 billion by 2029 - Exclusive Report by…
Browse in-depth TOC on "Natural Dyes Market". Browse in-depth TOC on "Natural Dyes Market". 210 – Tables 89 – Figures 220 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=78173284 "Plant Based Dyes is projected to be the fastest growing type of natural dyes, in terms of value, during the forecast period." Natural dyes which are derived from various parts of plants, including pods, bark, leaves, fruits and leaves are called...
PR Newswire
12/09/2024
Alex Therapeutics has signed an exclusive agreement with Navamedic for the…
Parkinson's disease is a neurodegenerative disorder associated with loss of motor skills and non-motor functions such as cognitive ability, which can make it difficult to manage treatments. Digital health tools provide an opportunity to support patients with functions such as reminders and treatment logs. Parkinson's disease is a neurodegenerative disorder associated with loss of motor skills and non-motor functions such as cognitive ability, which can make it difficult to manage treatments...
PR Newswire
12/09/2024
Trading by management and close relations of management
Please read the full announcement in PDF Attachment 2024_36_Trading_By_Management
Nasdaq GlobeNewswire
12/09/2024
Altri Comunicati